PeptideDB

Biperiden

CAS: 514-65-8 F: C21H29NO W: 311.46

Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders[1][2].
Invitro Biperiden (29.6 μg/ml, 72 hours) can significantly induce apoptosis and inhibit proliferation at high doses in human pancreatic ductal adenocarcinoma cells[1]. Cell Proliferation Assay[1] Cell Line:
In Vivo Biperiden (intraperitoneal injection, 10 mg/kg, everyday, 3 weeks) reduces tumor size by 83% in subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells[1]. Biperiden (intraperitoneal injection, 8 mg/kg, every 8 hours, 10 days) can reduce frequency of spontaneous seizures and extracellular hippocampal glutamate levels while cause a long-term decrease in hippocampal excitability[2]. Animal Model:
Name Biperiden
CAS 514-65-8
Formula C21H29NO
Molar Mass 311.46
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Leonie Konczalla,et al. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Int J Cancer. 2020 Mar 15;146(6):1618-1630. [2]. Simone Bittencourt, et al. Modification of the natural progression of epileptogenesis by means of biperiden in the pilocarpine model of epilepsy. Epilepsy Res. 2017 Dec;138:88-97. doi: 10.1016/j.eplepsyres.2017.10.019. Epub 2017 Oct 29. [3]. Pehl C, et al. Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. Aliment Pharmacol Ther. 1998 Oct;12(10) [4]. Kornhuber J, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8) [5]. Myhrer T, et al. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. Pharmacol Biochem Behav. 2008 Jun;89(4):633-8.